Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Non-Current Deferred Tax Liability (2016 - 2025)

Kiora Pharmaceuticals' Non-Current Deferred Tax Liability history spans 10 years, with the latest figure at $102152.0 for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability fell 79.18% year-over-year to $102152.0; the TTM value through Dec 2025 reached $102152.0, down 79.18%, while the annual FY2025 figure was $102152.0, 79.18% down from the prior year.
  • Non-Current Deferred Tax Liability reached $102152.0 in Q4 2025 per KPRX's latest filing, down from $490690.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $802131.0 in Q4 2021 to a low of $102152.0 in Q4 2025.
  • Average Non-Current Deferred Tax Liability over 5 years is $665544.1, with a median of $728926.0 recorded in 2021.
  • Peak YoY movement for Non-Current Deferred Tax Liability: soared 99.51% in 2021, then plummeted 79.18% in 2025.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $802131.0 in 2021, then changed by 0.0% to $802131.0 in 2022, then decreased by 2.83% to $779440.0 in 2023, then tumbled by 37.05% to $490690.0 in 2024, then tumbled by 79.18% to $102152.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Non-Current Deferred Tax Liability are $102152.0 (Q4 2025), $490690.0 (Q3 2025), and $490690.0 (Q2 2025).